AstraZeneca And Daiichi Eyeing Tumor-Agnostic Future For Enhertu?
Pan-Tumor Approach Pays Off So Far
Executive Summary
The ability of Daiichi-Sankyo/AstraZeneca’s blockbuster antibody-drug conjugate Enhertu to tackle a range of HER2-expressing cancers in a Phase II study could lead to a tumor-agnostic future for the product, new data suggest.
You may also be interested in...
Enhertu Is First ADC Approved For Tumor-Agnostic Indication
The US Food and Drug Administration approved Daiichi Sankyo/AstraZeneca’s Enhertu for metastatic HER2-positive solid tumors.
It’s Official: The Merck-Daiichi Deal Has The Biggest Upfront Ever
But the partners will have to avoid the pitfalls that have bedevilled several other expensive licensing deals.
Daiichi Sankyo Comes Out Swinging At WCLC As ADCs Steal Show
The Japanese drug maker gave multiple presentations on AstraZeneca-partnered Enhertu and other deruxtecan-based ADCs. Plus Gilead presented data on Trodelvy, Amgen showed early frontline data for Lumakras, and J&J’s EGFR-directed bispecific Rybrevant showed a 50% ORR in heavily pretreated patients.